• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝肠循环和尿黑酸在 alkaptonuria 小鼠模型中的主要排泄途径。

Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.

机构信息

Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

School of Sport & Exercise Sciences, Liverpool John Moores University, Liverpool, UK.

出版信息

J Inherit Metab Dis. 2024 Jul;47(4):664-673. doi: 10.1002/jimd.12728. Epub 2024 Mar 15.

DOI:10.1002/jimd.12728
PMID:38487984
Abstract

Altered activity of specific enzymes in phenylalanine-tyrosine (phe-tyr) metabolism results in incomplete breakdown of various metabolite substrates in this pathway. Increased biofluid concentration and tissue accumulation of the phe-tyr pathway metabolite homogentisic acid (HGA) is central to pathophysiology in the inherited disorder alkaptonuria (AKU). Accumulation of metabolites upstream of HGA, including tyrosine, occurs in patients on nitisinone, a licenced drug for AKU and hereditary tyrosinaemia type 1, which inhibits the enzyme responsible for HGA production. The aim of this study was to investigate the phe-tyr metabolite content of key biofluids and tissues in AKU mice on and off nitisinone to gain new insights into the biodistribution of metabolites in these altered metabolic states. The data show for the first time that HGA is present in bile in AKU (mean [±SD] = 1003[±410] μmol/L; nitisinone-treated AKU mean [±SD] = 45[±23] μmol/L). Biliary tyrosine, 3(4-hydroxyphenyl)pyruvic acid (HPPA) and 3(4-hydroxyphenyl)lactic acid (HPLA) are also increased on nitisinone. Urine was confirmed as the dominant elimination route of HGA in untreated AKU, but with indication of biliary excretion. These data provide new insights into pathways of phe-tyr metabolite biodistribution and metabolism, showing for the first time that hepatobiliary excretion contributes to the total pool of metabolites in this pathway. Our data suggest that biliary elimination of organic acids and other metabolites may play an underappreciated role in disorders of metabolism. We propose that our finding of approximately 3.8 times greater urinary HGA excretion in AKU mice compared with patients is one reason for the lack of extensive tissue ochronosis in the AKU mouse model.

摘要

苯丙氨酸-酪氨酸(phe-tyr)代谢中特定酶活性的改变导致该途径中各种代谢物底物的不完全分解。生物流体中phe-tyr 代谢物同型胱氨酸(HGA)浓度的增加和组织积累是遗传性疾病尿黑酸尿症(AKU)发病机制的核心。在 nitisinone(一种用于 AKU 和遗传性酪氨酸血症 1 型的许可药物)治疗的患者中,HGA 上游的代谢物,包括酪氨酸,也会积累,nitisinone 抑制了负责 HGA 产生的酶。本研究旨在研究 AKU 小鼠在 nitisinone 治疗和未治疗时关键生物体液和组织中的 phe-tyr 代谢物含量,以深入了解这些代谢改变状态下代谢物的分布情况。数据首次表明,HGA 存在于 AKU 的胆汁中(平均值[±标准差] = 1003[±410] μmol/L;nitisinone 治疗的 AKU 平均值[±标准差] = 45[±23] μmol/L)。胆汁中的酪氨酸、3(4-羟苯基)丙酮酸(HPPA)和 3(4-羟苯基)乳酸(HPLA)也在 nitisinone 治疗时增加。未经治疗的 AKU 中,尿液是 HGA 的主要排泄途径,但有胆汁排泄的迹象。这些数据提供了 phe-tyr 代谢物分布和代谢途径的新见解,首次表明肝胆排泄有助于该途径中代谢物的总池。我们的数据表明,有机酸酸和其他代谢物的胆汁排泄可能在代谢紊乱中发挥了被低估的作用。我们提出,我们在 AKU 小鼠中发现的 HGA 排泄量比患者高约 3.8 倍,这是 AKU 小鼠模型中组织褐黄病不广泛的原因之一。

相似文献

1
Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.肝肠循环和尿黑酸在 alkaptonuria 小鼠模型中的主要排泄途径。
J Inherit Metab Dis. 2024 Jul;47(4):664-673. doi: 10.1002/jimd.12728. Epub 2024 Mar 15.
2
Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.在对 alkaptonuria 进行 nitisinone 治疗期间,对酪氨酸代谢途径代谢物通量的定量。
Sci Rep. 2019 Jul 11;9(1):10024. doi: 10.1038/s41598-019-46033-x.
3
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.尼替西农治疗尿黑酸尿症 1 型(SONIA 1)的适用性:一项国际、多中心、随机、开放标签、无治疗对照、平行分组、剂量反应研究,旨在探究尼替西农每日一次给药对治疗 4 周后尿黑酸尿症患者 24 小时尿同型胱氨酸排泄量的影响。
Ann Rheum Dis. 2016 Feb;75(2):362-7. doi: 10.1136/annrheumdis-2014-206033. Epub 2014 Dec 4.
4
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.限制酪氨酸和苯丙氨酸的饮食可降低与黑尿症的尼替西农治疗相关的酪氨酸血症。
J Inherit Metab Dis. 2020 Mar;43(2):259-268. doi: 10.1002/jimd.12172. Epub 2020 Jan 13.
5
Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.对羟苯乙酸不仅通过肾小球滤过和肾小管分泌清除,而且在黑尿酸症患者的肾脏中也产生。
J Inherit Metab Dis. 2020 Jul;43(4):737-747. doi: 10.1002/jimd.12181. Epub 2020 Feb 5.
6
Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.重新审视长期服用尼替西农治疗黑尿症期间尿黑酸途径中苯丙氨酸/酪氨酸通量的量化
Metabolites. 2022 Sep 29;12(10):920. doi: 10.3390/metabo12100920.
7
Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.对羟基苯丙酮酸、对羟基苯乳酸和酪氨酸对常规血清和尿液临床化学检测的干扰;对用尼替西农治疗的尿黑酸尿症患者生化监测的影响。
Clin Biochem. 2019 Sep;71:24-30. doi: 10.1016/j.clinbiochem.2019.06.010. Epub 2019 Jun 20.
8
Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.高苯丙氨酸血症患者尼替西农治疗期间酪氨酸血症的决定因素。
Sci Rep. 2022 Sep 27;12(1):16083. doi: 10.1038/s41598-022-20424-z.
9
Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.尼替西农可阻止褐黄病并降低尿黑酸尿症的进展速度:评价尼替西农在英国国家褐黄病中心的疗效。
Mol Genet Metab. 2018 Sep;125(1-2):127-134. doi: 10.1016/j.ymgme.2018.07.011. Epub 2018 Jul 24.
10
Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.黑尿酸症小鼠模型中的褐黄病性骨关节病,以及尼替西农对此的抑制作用。
Ann Rheum Dis. 2014 Jan;73(1):284-9. doi: 10.1136/annrheumdis-2012-202878. Epub 2013 Mar 19.

引用本文的文献

1
Alterations in the gut microbiota in individuals with infantile cholestasis: a comparison of high- and low-γ-glutamyltransferase subtypes.婴儿胆汁淤积症患者肠道微生物群的改变:高γ-谷氨酰转移酶和低γ-谷氨酰转移酶亚型的比较
Transl Pediatr. 2025 Jun 27;14(6):1263-1277. doi: 10.21037/tp-2025-183. Epub 2025 Jun 25.